Additionally, S100B levels have been suggested to stratify the different stages of the disease, with the highest concentrations being found in relapsing remitting MS patients in opposite to lowest levels in progressive MS (Bartosik-Psujek et al., 2011; Barateiro et al., 2016). Here, S100B is linked to myeloid sarcoma.